JAK-inhibition in Recurrent Classical Hodgkin Lymphoma
Status:
Completed
Trial end date:
2019-05-17
Target enrollment:
Participant gender:
Summary
The Purpose of this trial is:
- to determine the overall response rate (ORR, complete response [CR] + partial response
[PR]) in patients with relapsed or refractory HL
- to determine the safety profile of ruxolitinib in patients with relapsed or refractory
HL